A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

GlaxoSmithKline (GSK)

Status and phase: Terminated; Phase 1

Conditions: Hematologic Diseases; Anaemia, Sickle Cell

Treatments: Other: Placebo; Drug: GSK4172239D

Study type: Interventional

Funder types: Industry

Identifiers

NCT05660265

218471

Details and patient eligibility

About

This will be a first time in human (FTIH) study in sickle cell diseases (SCD) participants. The FTIH study is planned to evaluate the safety, tolerability, and pharmacokinetics of GSK4172239D.

The study will be composed of 3 periods for all participants (Screening, Treatment, and Follow up). Participants will be screened and, prior to first dose on Day 1, will be randomized to receive either GSK4172239D or placebo.

GSK4172239D is a prodrug that is converted in vivo into GSK4106401. This study will be a single dose, dose-escalation study. The initial dosing for all cohorts will be staggered so that 2 participants will be dosed as sentinel participants. Provided there are no safety concerns in 48 hours (h), the remaining 6 participants scheduled for the cohort may be dosed. One selected cohort of participants will also receive an additional single dose of GSK4172239D (or matching placebo) under fed (high calorie and high fat) conditions after a washout period of a minimum of 20 days or 5 half-lives, whichever is longer, designated as the Food Effect Cohort.

Enrollment: 11 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants diagnosed with SCD not taking medication which increases gamma-globin (fetal hemoglobin).
• Participants with SCD who have failed or not tolerated one or more approved therapies for SCD
• Body weight greater than (>) 50 kilogram (kg).
• For male participants: Refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR agree to use a male condom with female partner. Agree to use an additional highly effective contraceptive method with a failure rate of less than (<) 1% per year when having sexual intercourse with a woman of childbearing potential who is not currently pregnant
• For female participants: Female participants are eligible to participate if they are a woman of non-childbearing potential (WONCBP).
• Capable of giving informed consent.

Exclusion criteria

• Presence of active, clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data.
• Clinically significant abnormal blood pressure and/or history of hypertension as determined by the investigator.
• History of clinically significant heart disease as determined by the investigator.
• Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m^2
• ALT > 3x upper limit of normal (ULN).
• Bilirubin > 5x ULN (isolated bilirubin > 5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
• Hemoglobin < 6 gram/decalitre (g/dL).
• Absolute neutrophil count <1,500 / microlitre (μL).
• Platelet count <75,000 /μL or >750,000 /μL.
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 t1/2 (whichever is longer) prior to the first dose of study drug, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise participant safety. By exception, participant may take acetaminophen (less than or equal to [≤] 2 g/day) up to 48h prior to the first dose of study drug.
• Use of hydroxyurea or decitabine within 9 weeks prior to baseline through follow-up.
• Blood transfusion within 3 months prior to baseline through follow-up.
• Current enrollment or past participation within the last 30 days before signing of consent in this or any other clinical study involving an investigational study drug or any other type of medical research.
• Positive pre-study drug/alcohol screen. By exception, opioid use for pain or benzodiazepine use for anxiety as directed by a physician is permitted.
• Regular use of known drugs of abuse, except for use directed by a physician. By exception, opioid use for pain or benzodiazepine use for anxiety is permitted.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

11 participants in 6 patient groups

Cohort 1

Experimental group

Description:

Participants in this arm will receive either single dose of GSK4172239D (Dose 1) or matching placebo.

Treatment:

Drug: GSK4172239D

Other: Placebo

Cohort 2

Experimental group

Description:

Participants in this arm will receive either single dose of GSK4172239D (Dose 2) or matching placebo.

Treatment:

Drug: GSK4172239D

Other: Placebo

Cohort 3

Experimental group

Description:

Participants in this arm will receive either single dose of GSK4172239D (Dose 3) or matching placebo.

Treatment:

Drug: GSK4172239D

Other: Placebo

Cohort 4

Experimental group

Description:

Participants in this arm will receive either single dose of GSK4172239D (Dose 4) or matching placebo.

Treatment:

Drug: GSK4172239D

Other: Placebo

Cohort 5

Experimental group

Description:

Participants in this arm will receive either single dose of GSK4172239D (Dose 5) or matching placebo.

Treatment:

Drug: GSK4172239D

Other: Placebo

Food effect cohort

Experimental group

Description:

One selected cohort will also receive an additional single dose of GSK4172239D (or matching placebo) under fed (high calorie and high fat) conditions.

Treatment:

Drug: GSK4172239D

Other: Placebo